Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Recommendation of “Buy” from Brokerages

Replimune Group, Inc. (NASDAQ:REPL) has been given a consensus recommendation of “Buy” by the eight research firms that are covering the firm, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $19.43.

A number of brokerages recently weighed in on REPL. BMO Capital Markets boosted their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. HC Wainwright upped their price objective on Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. raised their target price on Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Finally, Jefferies Financial Group increased their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, December 4th.

Replimune Group Price Performance

REPL opened at $10.82 on Monday. The company has a market capitalization of $833.30 million, a P/E ratio of -3.52 and a beta of 1.30. The company has a 50-day moving average of $12.66 and a 200-day moving average of $12.16. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. Replimune Group has a 1-year low of $4.92 and a 1-year high of $17.00.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Equities analysts expect that Replimune Group will post -2.97 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Sterling Capital Management LLC grew its stake in Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock valued at $26,000 after purchasing an additional 1,655 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in Replimune Group by 696.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock worth $82,000 after purchasing an additional 5,922 shares during the last quarter. Aster Capital Management DIFC Ltd lifted its stake in shares of Replimune Group by 8,798.9% in the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock worth $100,000 after buying an additional 8,183 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Replimune Group during the 4th quarter worth $117,000. Finally, Quantinno Capital Management LP bought a new stake in Replimune Group during the fourth quarter valued at about $127,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.